Seres Therapeutics, Inc. current report, 30 January 2018

Full document

Seres Therapeutics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on January 30, 2018. The company is a biotechnology firm incorporated in Delaware and is classified as an emerging growth company. The report addresses a specific corporate governance event regarding executive leadership.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.

Material Changes

On January 30, 2018, the Company appointed Eric D. Shaff to the additional role of Chief Operating Officer (COO). Mr. Shaff will continue to serve in his existing roles as Executive Vice President, Chief Financial Officer, and Treasurer. His expanded executive responsibilities now include:

  • General and administrative functions (finance, information technology, human resources, and facilities).
  • Business development.
  • Corporate strategy.
  • Commercial operations.

Management Commentary and Background

Mr. Shaff, age 42, has served as the Company's CFO and Executive Vice President since November 2014. Prior to joining Seres, he held positions at Momenta Pharmaceuticals, Inc. (2012-2014) and Genzyme Corporation (2004-2011). He also serves on the Board of Directors for Sigilon Therapeutics, Inc. The appointment is governed by an existing employment agreement dated June 14, 2015, and an indemnification agreement dated November 17, 2014.

Investor Verification Checklist

  • Confirm the effective date of the COO appointment (January 30, 2018).
  • Review the scope of Mr. Shaff's new responsibilities regarding commercial operations and business development.
  • Verify the terms of the existing employment agreement (Exhibit 10.7 to Form S-1) to understand compensation implications of the expanded role.
  • Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.